for investors and financial analysts on Tuesday, 3 December 2002
Address: Trinity Square
| Source: Orion Oyj
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary...
Read MoreORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2026 April–June 2026 Highlights Net sales totalled EUR 521.6...
Read More